🔴 Recursion Pharmaceuticals is trading 4.1% down today with no clear company-specific catalyst

Recursion Pharmaceuticals is trading 4.1% down at $3.73, with no clear company-specific explanation for the decline.

• No new company-specific announcement, filing, clinical update, or analyst action clearly explains the September 25, 2026 decline.
• Recent coverage highlights the expanded Tempus AI partnership and earlier Morgan Stanley presentation; both predate today’s move.
• Broader markets are nearly flat, so the decline cannot be confidently attributed to market-wide selling.